NCT06352554 (STING) is a clinical trial in Diagnosis, sponsored by SpeeDx Pty Ltd.

Who is sponsoring NCT06352554?

NCT06352554 is sponsored by SpeeDx Pty Ltd.

What condition does NCT06352554 study?

NCT06352554 studies Diagnosis, Gonorrhea, Resistance Bacterial.

Is NCT06352554 still recruiting?

NCT06352554 is currently not yet recruiting. Last updated 9 April 2024.

Last reviewed 2024-04-09 · How we verify

NCT06352554: STING

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Susceptibility Testing In Neisseria Gonorrhoeae (STING) Study, Assessing the Performance of a New Rapid Test for Gonorrhoea Antibiotic Resistance, in a Cohort of 100 Culture Positive Neisseria Gonorrhoeae Infections

Not yet recruiting Last updated 9 April 2024

What this trial tests

trial in Diagnosis in 100 participants. Not yet recruiting.

Timeline

8 April 2024

Primary endpoint
30 December 2024

30 January 2025

Quick facts

Lead sponsor	SpeeDx Pty Ltd
Status	Not yet recruiting
Study type	OBSERVATIONAL
Enrollment	100
Start date	8 April 2024
Primary completion	30 December 2024
Estimated completion	30 January 2025

Conditions studied

Diagnosis — all drugs for Diagnosis →
Gonorrhea — all drugs for Gonorrhea →
Resistance Bacterial — all drugs for Resistance Bacterial →

Sponsor

SpeeDx Pty Ltd — full company profile →

Who can join

18 and older, any sex, with Diagnosis or Gonorrhea. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This study aims to validate a novel antibiotic susceptibility test (InSignia) for gonorrhoea in patient clinical samples. The hypothesis is that the InSignia test will be able to detect transcriptional responses after incubation in antibiotic for susceptible strains and not resistant strains. Furthermore, this study will also add to our understanding on the performance of this test in various clinical specimens.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other recruiting trials for Diagnosis

Currently open trials in the same condition.

NCT07352475 — Reasoning Enrichment With Feedback From IA in NEphrology Trial · NA · recruiting
NCT07138768 — Role of MRI in the Early Diagnosis and Management of Acute Stroke and Its Impact on Turnaround Time in Emergency Setting · recruiting
NCT07051668 — The RightCall: Implementing a Sepsis Diagnostic Toolkit to Improve Pediatric Diagnosis in ED Transfer Calls · NA · recruiting
NCT07108725 — Non-invasive Diffusion-weighted Imaging With MRCP in the Diagnosis of Neoplastic Biliary Obstruction · recruiting
NCT06517901 — Fusion or Cognitive Ultrasound-guided Biopsy to Detect Prostate Cancer · NA · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT06352554 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by SpeeDx Pty Ltd
Last refreshed: 9 April 2024

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06352554.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing